Floatz logo

Lurbinectedin

Small Cell Lung Carcinoma

Sichuan UniversitySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
65/ 100

Competitive context

276 Active assets in the Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
Anti-Pd-L1 Monoclonal Antibody Shr-1316
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Berzosertib
National Cancer Institute (NCI)
Phase 2BBB
Etoposide
Sichuan University
Phase 4BBB
Cis-Diamminedichloroplatinum Ii
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Lurbinectedin is also rated in:

small cell carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
neuroendocrine carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
lung carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →